Login to Your Account

Domain Inks $180M Early Stage GPCR Deal with Merck Serono

By Nuala Moran

Wednesday, January 19, 2011
Domain Therapeutics SA sealed a collaboration potentially worth €134 million (US$179.6 million) plus royalties for a discovery-stage program targeting a G protein-coupled receptor (GPCR) implicated in Parkinson's and other neurodegenerative diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription